ArticleCell death & disease2026
KDM5B cooperates with CRL4B complex to promote the tumorigenesis of ER+ breast cancer via regulating cholesterol metabolism.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Estrogen receptor-positive (ER+) breast cancer is the predominant subtype of breast cancer, and its development is closely linked to metabolic reprogramming, including alterations in cholesterol metabolism. Therefore, this study aimed to investigate the functional interplay between lysine demethylase 5B (KDM5B) and the Cullin-RING ligase 4B (CRL4B) complex in modulating cholesterol metabolism to promote ER+ breast cancer progression. Immunohistochemical assays and bioinformatic analysis of various cancer databases were performed to examine KDM5B expression levels in breast cancer. Additionally, KDM5B overexpression and knockdown were performed to investigate the role of KDM5B in breast cancer cell proliferation and progression. Notably, we identified physical and functional interactions between KDM5B and the CRL4B subunits, CUL4B and DDB1. Mechanistically, KDM5B recruits CRL4B to the promoters of INSIG1 and INSIG2, which are key regulators of cholesterol biosynthesis and uptake, and suppresses their expression by upregulating H2AK119ub1 and downregulating H3K4me3 histone marks, thereby promoting the proliferation, migration, and invasion of tumor cells. Functional assays revealed that disruption of the KDM5B-CRL4B axis impairs cholesterol homeostasis and inhibits tumor growth. KDM5B upregulation was significantly negatively correlated with the survival rates in various cancer types, including thyroid, lung, esophageal and colorectal cancers. Overall, these findings establish a novel regulatory axis in cholesterol metabolism, uncover potential therapeutic vulnerabilities in ER+ breast cancer, and suggest that targeting the KDM5B could provide a strategy to curb tumor progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.